Beam Therapeutics Inc. completed its acquisition of Orbital Therapeutics, Inc. on 2025-12-08, according to the Form 8-K Beam Therapeutics Inc. filed with the SEC on 2025-12-11. The filing states a price of $255.1 million.
| Acquirer | Beam Therapeutics Inc. |
|---|---|
| Acquired | Orbital Therapeutics, Inc. |
| Completed | 2025-12-08 |
| Price stated in the filing | $255.1 million |
| Reported by | Beam Therapeutics Inc. (BEAM), the buyer |
| Filing | Form 8-K, filed 2025-12-11 |
Want the whole picture on Beam Therapeutics Inc.?
Example from a real report (our sample on Target): “In March 2026, Target announced a planned incremental $1 billion operating investment” Source: Target Corporation (press release)
A Full Report on Beam Therapeutics Inc.: verified, sourced, every claim cited, ready in a few minutes. See pricing.
What the Full Report on Beam Therapeutics Inc. covers
The Short Answer
Which Company This Is
What They Do, And How The Money Works
Who Runs It, And How To Reach Them
The Money: Funding, Valuation, Runway
Who Pays Them, And Who They Are Up Against
Warning Bells
Sources
1 cited source found
Plus the sections for what you are deciding, which you pick after ordering.
A real finished report, first screen. Opens in a new tab.
What the filing says
On December 8, 2025, Bristol-Myers Squibb Company ("BMS") completed its previously announced acquisition of Orbital Therapeutics, Inc. ("Orbital") pursuant to an Agreement and Plan of Merger dated October 10, 2025 between Orbital and BMS (the "Acquisition").
The price, in the filing's words
At the closing of the Acquisition, such shares were cancelled and converted into $255.1 million in closing cash consideration, plus the right to receive up to approximately $26.3 million in additional cash consideration upon the release, if any, of certain escrows.
More from the filing
Prior to the closing of the Acquisition, Beam Therapeutics Inc. (the "Company") held 75 million shares of Orbital common stock, which represented a fully diluted ownership stake of approximately 17%.
The Company plans to provide an update on its anticipated cash runway, taking into consideration proceeds from the Acquisition, in connection with the 2026 J.P. Morgan Healthcare Conference.
Quoted from Beam Therapeutics Inc.'s Form 8-K.
This is the only completed acquisition Beam Therapeutics Inc. reported under Item 2.01 in the last twelve months.
Who runs it now, who owns it, where the money comes from and what to watch for, every claim linked to its source.
Order Full Report on Beam Therapeutics Inc.Look up Beam Therapeutics Inc. and see what is on record before you decide.
Get the free SnapshotWhere this comes from
A public company must file a current report on Form 8-K with the SEC within four business days of completing a significant acquisition or disposition of assets, under Item 2.01 of the report. The acquired company sometimes files one too, when the deal makes it a subsidiary of the buyer.
Every fact on this page is taken from one of those filings and linked to it: which company acquired which, the date the filing gives for completion, and the price when the filing states one in dollars, shown next to the sentence that states it. A filing states what was bought and on what terms; it rarely states why, and neither does this page.